Pharmaceutical giant Merck has announced its acquisition of Verona Pharma, a company specializing in treatments for respiratory diseases, in a deal valued at approximately $10 billion. This strategic move allows Merck to enhance its portfolio with Verona Pharma’s chronic obstructive pulmonary disease (COPD) medication, Ohtuvayre, which received approval from the Food and Drug Administration in June 2024 for long-term treatment of COPD in adults.
Merck’s Chairman and CEO, Robert Davis, emphasized that Ohtuvayre not only complements its existing offerings but also promises both near- and long-term growth and value for shareholders. Meanwhile, David Zaccardelli, President and CEO of Verona Pharma, expressed confidence that Merck’s extensive commercial network and exceptional clinical resources will help expedite the reach of Ohtuvayre to a greater number of patients suffering from COPD.
Both companies’ boards have approved the deal, which is anticipated to finalize in the fourth quarter, pending approval from Verona Pharma’s shareholders and confirmation from the High Court of Justice of England and Wales.
This acquisition marks a significant advancement in the fight against respiratory diseases, potentially offering millions of COPD patients improved access to essential treatments. The collaboration between two leading entities could lead to more innovative solutions in the future, inspiring hope in the healthcare community.